ArticleInternational journal of general medicine2026
Integrated Multi-Omics Analysis Constructs an Intratumoral Heterogeneity-Corrected Prognostic Signature for Cervical Cancer.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tumor heterogeneity challenges the accuracy of existing prognostic models for cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC). Prognostic models that correct for tumor heterogeneity remain unexplored. Methods: Based on the GSE5787 dataset comprising 33 multiregional samples from 11 patients with CESC, we calculated both interpatient heterogeneity (IPH) and intratumoral heterogeneity (ITH) scores. Genes with low heterogeneity were selected to construct a prognostic model using the CESC cohort from The Cancer Genome Atlas (TCGA). Key gene expression was validated in HeLa and SiHa cell lines. The functional consequences of gene knockout were assessed through Cell Counting Kit-8 (CCK-8) proliferation assays, wound healing migration assays, and Transwell assays. Results: Genes exhibiting low heterogeneity were predominantly associated with energy metabolism pathways, whereas those displaying high heterogeneity were enriched in immune-related signaling pathways. The risk score based on Armadillo Repeat Containing X-Linked 1 (ARMCX1) and Signal Transducing Adaptor Family Member 2 (STAP2) achieved area under the curve (AUC) values of 0.74, 0.68, and 0.74 for predicting 1-year, 3-year, and 5-year overall survival, respectively. Importantly, this signature demonstrated robust performance with a risk classification inconsistency rate of merely 18%, outperforming 10 previously published CESC prognostic models. The integrative nomogram incorporating both the risk score and clinical staging demonstrated enhanced prognostic accuracy. Although patients in the high-risk group exhibited diminished immunotherapy efficacy, drug sensitivity screening identified seven potentially effective therapeutic agents as alternative treatment options. In vitro experiments demonstrated that STAP2 knockdown suppressed HeLa cell proliferation, migration, and invasive capacity. Conclusion: This study establishes a robust gene signature through ITH correction, which may mitigate single-region sampling bias and offers a promising tool for prognostic stratification in CESC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.